Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Association of tissue factor (TF) and CD147 overexpression with extracellular vesicle (EV) production and invasion potential. The expression of green fluorescent protein (GFP)-fusion CD147 on the plasma membrane of J82 cells was observed using confocal microscopy ( A ). To assess the vesicular export of CD147, GFP-labeled vesicles were derived from J82 cells transfected with the CD147-GFP construct and analyzed using flow cytometry ( B ). The lysates of the EVs were prepared using 0.1% Triton™ X-100. EVs were derived from human bladder urothelial carcinoma J82 cells co-transfected with TF and CD147 plasmids. The EVs were quantified using NTA in the 48-h culture supernatant of J82 cells overexpressing CD147 and TF versus that of the control transfection condition ( C ). Invasion potency was measured by a Transwell assay, with 6–8 images of the cells that had passed through the coated microporous membrane after 24 h per experiment ( D )

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Over Expression, Expressing, Membrane, Confocal Microscopy, Labeling, Derivative Assay, Transfection, Construct, Flow Cytometry, Transwell Assay

Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of the combined inhibitors treatment on extracellular vesicle (EV)-induced migration potential. J82 human bladder urothelial carcinoma cells were exposed to 150 µg/ml protein from J82 cell-derived EVs and treated with either 5 µM CD147 inhibitor AC-73 alone ( A ) or a combination of 2.5 µM AC-73 and tissue factor pathway inhibitor (TFPI, 300 ng/ml, B ) for 16 h. Relative migration was quantified via a Transwell assay utilizing 6–8 images of cells that traversed the microporous membrane per experiment

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Migration, Derivative Assay, Transwell Assay, Membrane

Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of treatment with the combined inhibitors on extracellular vesicle (EV)-induced matrix metalloproteinases (MMPs) release. J82 human bladder urothelial carcinoma cells were treated with J82 cell-derived EVs or with a pool of isolated EVs from urine samples collected from patients with muscle-invasive bladder cancer ( A ), along with either 2.5 µM or 5 µM of the CD147 inhibitor AC-73, in the absence or presence of tissue factor pathway inhibitor (TFPI, 300 ng/ml, B ) for 24 h. Recombinant CD147 (rCD147) was used as a positive control to induce MMP activity. The induction of MMPs was measured using colorimetric enzymatic methods

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Derivative Assay, Isolation, Recombinant, Positive Control, Activity Assay

Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of treatment with the combined inhibitors on extracellular vesicle (EV)-induced invasion potential. J82 human bladder urothelial carcinoma cells were exposed to 150 µg/ml protein from J82 cell-derived EVs or with a pool of isolated EVs from urine samples collected from patients with muscle-invasive bladder cancer, and treated with either 5 µM of the CD147 inhibitor AC-73 alone ( A ) or a combination of 2.5 µM AC-73 and tissue factor pathway inhibitor (TFPI, 300 ng/ml, B ) for 24 h. Invasion potency was measured via a Transwell assay utilizing 6–8 images of cells that traversed the microporous membrane per experiment

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Derivative Assay, Isolation, Transwell Assay, Membrane

Journal: Cell Communication and Signaling : CCS

Article Title: Targeting cancer-derived extracellular vesicles by combining CD147 inhibition with tissue factor pathway inhibitor for the management of urothelial cancer cells

doi: 10.1186/s12964-024-01508-x

Figure Lengend Snippet: Impact of treatment with the combined inhibitors on the extracellular vesicle (EV) binding capability. J82 human bladder urothelial carcinoma cells were exposed in suspension to carboxyfluorescein succinimidyl ester fluorescent dye (CFSE)-labeled J82 cell-derived EVs and treated with either 5 µM CD147 inhibitor AC-73 alone or a combination of 2.5 µM AC-73 and tissue factor pathway inhibitor (TFPI, 300 ng/ml). The cells were analyzed for green fluorescence in the FITC channel using flow cytometry

Article Snippet: J82 cells were exposed to their own isolated and characterized microvesicle-like EVs, which were pre-incubated with or without the CD147 inhibitor AC-73 (MedChemExpress LLC, NJ), human recombinant TFPI together with factor VII (Sigma-Aldrich, MO), or human recombinant CD147 protein (rCD147, Sino Biological Europe, Germany) for the specified duration.

Techniques: Binding Assay, Suspension, Labeling, Derivative Assay, Fluorescence, Flow Cytometry

Journal: Oncology Letters

Article Title: Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

doi: 10.3892/ol.2012.981

Figure Lengend Snippet: Correlation between EMMPRIN/CD147 expression and clinicopathological characteristics.

Article Snippet: The sections were blocked with 5% bovine serum albumin (Zhongshan, Beijing, China) in PBS solution for 20 min and probed with rabbit anti-human EMMPRIN/CD147 antibodies (1:300; Boster) at 4°C for 12 h. After washing, the bound antibodies were detected with biotinylated goat anti-rabbit IgG (1:100) and SABC complex at 30°C for 20 min.

Techniques: Expressing

Journal: Clinical Journal of the American Society of Nephrology : CJASN

Article Title: Expression of CD147 and Cyclophilin A in Kidneys of Patients with COVID-19

doi: 10.2215/CJN.09440620

Figure Lengend Snippet: The dysregulated CD147 and cyclophilin A (CypA) in kidney from COVID-19 cases. (A) The basolateral distribution of CD147 (1:6000, 10186-R125; Sino Biologic, Beijing, China) in the patient with glomerulitis without diagnostic morphologic abnormalities. (B) The staining of CD147 in autopsied tissue with acute tubular injury (ATI). (C) The CD147 expression in a deceased donor with ATI. (D and E) In patients with coronavirus disease 2019 (COVID-19), the distribution of CD147 shifts from basolateral to circumferential pattern. (F) The staining of CypA (1:200, sc-134310; Santa Cruz Biotechnology) in a patient without COVID-19 and without ATI. (G) The staining of CypA in autopsied tissue with ATI. (H and I) The staining of CypA in autopsied kidney tissues from patients with COVID-19 (the density of positively stained areas was evaluated by Image-Pro Plus 6.0 software; Media Cybernetics, Rockville, MD). Magnification, ×200 in A–E, G, and H; ×400 in F and I.

Article Snippet: The dysregulated CD147 and cyclophilin A (CypA) in kidney from COVID-19 cases . (A) The basolateral distribution of CD147 (1:6000, 10186-R125; Sino Biologic, Beijing, China) in the patient with glomerulitis without diagnostic morphologic abnormalities. (B) The staining of CD147 in autopsied tissue with acute tubular injury (ATI). (C) The CD147 expression in a deceased donor with ATI. (D and E) In patients with coronavirus disease 2019 (COVID-19), the distribution of CD147 shifts from basolateral to circumferential pattern. (F) The staining of CypA (1:200, sc-134310; Santa Cruz Biotechnology) in a patient without COVID-19 and without ATI. (G) The staining of CypA in autopsied tissue with ATI. (H and I) The staining of CypA in autopsied kidney tissues from patients with COVID-19 (the density of positively stained areas was evaluated by Image-Pro Plus 6.0 software; Media Cybernetics, Rockville, MD).

Techniques: Diagnostic Assay, Staining, Expressing, Software

Journal: Nature Communications

Article Title: Human Cyclophilin B forms part of a multi-protein complex during erythrocyte invasion by Plasmodium falciparum

doi: 10.1038/s41467-017-01638-6

Figure Lengend Snippet: Cyclophilin B interacts with Basigin (CD147/BSG), a critical merozoite invasion receptor on RBCs. a Co-localization of CypB and BSG on the surface of the RBC. RBCs were fixed and incubated with anti-CypB (mouse monoclonal) and anti-BSG (rabbit polyclonal) antibodies. The cells were stained with fluorochrome-conjugated secondary antibodies against CypB (green) and BSG (red) followed by confocal microscopy. CypB and BSG co-localized on the RBC surface with a Pearson’s coefficient of 0.53. b Merozoites were incubated with 25 µM of BSG protein for 2 h and detection was carried out using anti-CD147 antibody (rabbit polyclonal) and secondary fluorochrome-conjugated (red), followed by confocal microscopy. c CypB and BSG bind together on the merozoite surface. Merozoites were incubated with CypB and BSG proteins (25 µM each) for 2 h and binding was detected using anti-CypB (mouse monoclonal) and anti-BSG (rabbit polyclonal) antibodies followed by secondary antibodies and confocal microscopy. Supplementary Fig. illustrates in vitro interaction assays between CypB and BSG. Scale bar = 5 µm

Article Snippet: Recombinant proteins Cyclophilin B (Catlog: 11004-H08H-100) and Basigin (BSG/CD147, Catlog: 10186-H08H-100) were obtained commercially from Sino Biological Inc., China (Supplementary Fig. ).

Techniques: Incubation, Staining, Confocal Microscopy, Binding Assay, In Vitro

Journal: Frontiers in Neurology

Article Title: Thrombo-pathologic features and prognosis of acute ischemic stroke patients treated with remedial stent implantation

doi: 10.3389/fneur.2025.1659843

Figure Lengend Snippet: AIS patients in the RS group NRS group underwent thrombus IHC imaging (×100 magnification). The colors brown represent (a) NET, (b) CD163 (brown), (c) CRP (brown), (d) Actin (brown), (e) VWF (brown), and (f) CD147 (brown). Negative control images are not shown because of limited sample availability.

Article Snippet: Selected cerebral thrombus slices were subjected to immunohistochemical (IHC) staining for target proteins, including CD163 (Servicebio, GB113152 , 1:700), CD147 (BOSTER, A00248-1, 1:200), Actin (Alpha-actin-2, Servicebio, GB12044, 1:1000), CRP (Proteintech, 66250-1-Ig, 1:200), VWF (Servicebio, GB11020, 1:1,000), and marker of NETs—Citrullinated Histone H3 (CitH3, 97272, CST, 1: 1,000).

Techniques: Imaging, Negative Control

Journal: Frontiers in Neurology

Article Title: Thrombo-pathologic features and prognosis of acute ischemic stroke patients treated with remedial stent implantation

doi: 10.3389/fneur.2025.1659843

Figure Lengend Snippet: Violin plots compare the thrombopathologic characteristics of patients in the NRS and RS groups. Plots a and b reveal no differences in RBC and F/P between the two groups; plots c, d , and e reveal differences in thrombi between patients in the RS and NRS groups regarding the expression of NET, CD163, and CRP. Plots f, g , and h demonstrate CD147 in patients in the RS and NRS groups; thrombus expression of actin and vWF was not different. * denotes P < 0.05, ** denotes P < 0.01, and **** denotes P < 0.001.

Article Snippet: Selected cerebral thrombus slices were subjected to immunohistochemical (IHC) staining for target proteins, including CD163 (Servicebio, GB113152 , 1:700), CD147 (BOSTER, A00248-1, 1:200), Actin (Alpha-actin-2, Servicebio, GB12044, 1:1000), CRP (Proteintech, 66250-1-Ig, 1:200), VWF (Servicebio, GB11020, 1:1,000), and marker of NETs—Citrullinated Histone H3 (CitH3, 97272, CST, 1: 1,000).

Techniques: Expressing

Journal: Advanced Healthcare Materials

Article Title: Droplet Microarray Based Screening Identifies Proteins for Maintaining Pluripotency of hiPSCs

doi: 10.1002/adhm.202200718

Figure Lengend Snippet: Proteins used in this study with their corresponding structures and Protein Data Bank (PDB) codes

Article Snippet: Proteins (Thy‐1, EphB4, EphA1, E‐cadherin, coxackie and adenovirus receptor (CAR), JAM1, EpCAM, basigin (BSG), and dystroglycan (DAG1)) and rabbit anti‐CD147 antibody were purchased from Sino Biological Europe GmbH (Eschborn, Germany).

Techniques: Marker, Membrane, Protein Binding, Activation Assay, Migration, Stem Cell Culture